Akari Therapeutics, Plc Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Period Increase (Decrease)
Akari Therapeutics, Plc (AKTX) reported Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Period Increase (Decrease) of $54.00 thousand for the 3-month period ending 2025-03-31, per its 10-Q filed 2025-05-14.
Financial Statements › Notes › Fair Value Disclosures › Fair Value, Assets and Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation
us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease · last filed 2025-05-14
- Akari Therapeutics, Plc fair value, measurement with unobservable inputs reconciliation, recurring basis, liability, period increase (decrease) for the quarter ending 2025-03-31 was $54.00K.
- Akari Therapeutics, Plc fair value, measurement with unobservable inputs reconciliation, recurring basis, liability, period increase (decrease) for the quarter ending 2024-12-31 was -$1.56M.
- Akari Therapeutics, Plc fair value, measurement with unobservable inputs reconciliation, recurring basis, liability, period increase (decrease) for the quarter ending 2024-09-30 was -$30.00K.
- Akari Therapeutics, Plc fair value, measurement with unobservable inputs reconciliation, recurring basis, liability, period increase (decrease) for the quarter ending 2024-06-30 was $151.00K.
- Akari Therapeutics, Plc fair value, measurement with unobservable inputs reconciliation, recurring basis, liability, period increase (decrease) for fiscal 2024 was -$2.08M.
- Akari Therapeutics, Plc fair value, measurement with unobservable inputs reconciliation, recurring basis, liability, period increase (decrease) for fiscal 2023 was -$6.60M.
- Akari Therapeutics, Plc fair value, measurement with unobservable inputs reconciliation, recurring basis, liability, period increase (decrease) for fiscal 2022 was -$6.95M.
- Akari Therapeutics, Plc fair value, measurement with unobservable inputs reconciliation, recurring basis, liability, period increase (decrease) for fiscal 2013 was $286.00K.
| Period end | Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Period Increase (Decrease) 3 month | Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Period Increase (Decrease) 6 month | Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Period Increase (Decrease) 9 month | Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Period Increase (Decrease) 11 month | Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Period Increase (Decrease) 12 month |
|---|---|---|---|---|---|
| 2025-03-31 | $54.00K 10-Q · filed 2025-05-14 | -$1.50M derived: sum of 2 quarters · filed 2025-05-14 | -$1.53M derived: sum of 3 quarters · filed 2025-05-14 | -$1.38M derived: sum of 4 quarters · filed 2025-05-14 | |
| 2024-12-31 | -$1.56M derived: 10-K 12 month − 10-Q 9 month · filed 2025-04-15 | -$1.59M derived: sum of 2 quarters · filed 2025-04-15 | -$1.44M derived: sum of 3 quarters · filed 2025-04-15 | -$2.08M 10-K · filed 2025-04-15 | |
| 2024-09-30 | -$30.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-19 | $121.00K derived: sum of 2 quarters · filed 2024-11-19 | -$528.00K 10-Q · filed 2024-11-19 | ||
| 2024-06-30 | $151.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-19 | -$498.00K 10-Q · filed 2024-08-19 | |||
| 2024-03-31 | -$649.00K 10-Q · filed 2025-05-14 | ||||
| 2023-12-31 | -$6.60M 10-K · filed 2025-04-15 | ||||
| 2023-06-30 | -$6.15M 6-K · filed 2023-09-29 | ||||
| 2022-12-31 | -$6.95M 10-K · filed 2024-03-29 | ||||
| 2020-12-08 | -$556.81K 20-F · filed 2023-05-01 | ||||
| 2015-06-30 | -$210.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2015-08-12 | -$749.00K 10-Q · filed 2015-08-12 | |||
| 2015-03-31 | -$539.00K 10-Q · filed 2015-05-12 | ||||
| 2014-12-31 | $552.00K 10-Q · filed 2015-08-12 | ||||
| 2013-12-31 | $286.00K 10-K · filed 2015-02-11 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ELI LILLY & Co (LLY) | United States | $1,113.804B | 42.28 |
| JOHNSON & JOHNSON (JNJ) | United States | $652.528B | 29.10 |
| AbbVie Inc. (ABBV) | United States | $468.180B | 70.37 |
| Merck & Co., Inc. (MRK) | United States | $365.215B | 99.96 |
| ABBOTT LABORATORIES (ABT) | United States | $176.045B | 28.47 |
| PFIZER INC (PFE) | United States | $162.042B | 31.94 |
| VERTEX PHARMACEUTICALS INC / MA (VRTX) | United States | $132.481B | 28.56 |
| BRISTOL MYERS SQUIBB CO (BMY) | United States | $125.637B | 12.67 |
| REGENERON PHARMACEUTICALS, INC. (REGN) | United States | $74.751B | 21.53 |
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |